This activity is provided by Med Learning Group.
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Copyright © 2025 Med Learning Group. Built by Divigner. All Rights Reserved.
CME Bridge List
<< Back to CME Activities
Learn More & View Event » 
Learn More & View Event » 
Learn More & View Event » 
Learn More & View Event »
Show : Per page of 4
Use of Immunotherapy for Advanced Melanoma: Integrating Patient-Centric and Multidisciplinary Strategies
This interactive enduring activity is designed to help you optimize the development of treatment plans for your patients with advanced melanoma. Specifically, this program will provide a comprehensive review of the latest data on current and emerging immunotherapy approaches, and of effective strategies to mitigate and manage immunotherapy-associated adverse events. It will also share, expert appraisals of new treatment approaches through multiple clinical case scenarios, illustrative animations, and didactic presentations. Our goal is also to emphasize the importance of shared decision making while maintaining the patient’s well-being.
RELEASED DATE: June 28, 2024
EXPIRATION DATE: June 28, 2025
The ENCOMPASS Experience: Immunotherapy for Advanced Melanoma: Employing the Arts of Shared Decision-Making and Multidisciplinary Care
With multiple immunotherapy treatment options and combinations available for the management of advanced melanoma, clinicians require updates in the application of clinical data to guide shared decision-making and multidisciplinary care. In this concise program, Dr. Adil Daud reviews current evidence-based guidelines, clinical data informing treatment decisions, and demonstrates best practices for application of data in patients with advanced melanoma.
RELEASED DATE: July 24, 2024
EXPIRATION DATE: July 24, 2025
Immunotherapy-Based Combinations for Advanced Melanoma:
Best Practices, Key Developments, and a Look at the Horizon
This online enduring program will provide healthcare providers with information needed to select first-line treatment for patients with unresectable or metastatic melanoma by incorporating evidence-based guidelines and applying current clinical trial data. This program will also review best practices for the management of adverse events associated with immunotherapy for unresectable or metastatic melanoma, as well as outline combination immunotherapy strategies for patients with advanced melanoma.
RELEASED DATE: July 15, 2024
EXPIRATION DATE: July 15, 2025
An Innovative View: Evaluating Combination Checkpoint Inhibition Strategies in Advanced Melanoma: Considerations with Anti-LAG3 Antibodies
This online program is designed to help oncologists, dermatologists, nurse practitioners, oncology pharmacists, and physician's assistants to ensure confidence in the management of advanced melanoma. We aim to evaluate the pathophysiology of melanoma, including the rationale for use of anti-LAG3 antibodies in combination in advanced melanoma; assess the latest clinical data and clinical trial opportunities concerning the use of anti-LAG3 antibodies for combination in advanced melanoma; and recognize safety data with combination immunotherapy approaches in advanced melanoma.
RELEASED DATE: March 03, 2023
EXPIRATION DATE: March 03, 2024
